Breast Abscess Management

Primary Management Approach

• Incision and drainage is the primary treatment for breast abscesses, with antibiotics serving as adjunctive therapy, as recommended by the Infectious Diseases Society of America 1, 2

Antibiotic Selection

• The American College of Clinical Pharmacology recommends clindamycin 300-450 mg PO three times daily or 600 mg IV every 8 hours for breast abscess treatment, providing excellent coverage against Staphylococcus aureus (including MRSA) and streptococci 3, 4
• The Infectious Diseases Society of America suggests trimethoprim-sulfamethoxazole (TMP-SMX) 1-2 double-strength tablets twice daily as an alternative, effective against MRSA but with limited activity against β-hemolytic streptococci 3, 5
• Doxycycline or minocycline 100 mg twice daily is recommended by the American College of Clinical Pharmacology as an alternative option, effective against MRSA but with limited activity against streptococci, and not recommended for pregnant women or children under 8 years 3, 4
• Linezolid 600 mg twice daily is suggested by the Infectious Diseases Society of America as an alternative, effective against MRSA and streptococci, but more expensive than other options 3, 4
• Vancomycin 15-20 mg/kg IV every 8-12 hours is recommended by the American College of Clinical Pharmacology for severe infections or when parenteral therapy is required, and is the drug of choice for treatment of MRSA infections when IV therapy is needed 1, 4, 6

Treatment Duration

• The Infectious Diseases Society of America recommends 5-10 days of antibiotic therapy for skin and soft tissue infections, with treatment extended if the infection has not improved within this time period 2, 5

Common Pitfalls to Avoid

• Delaying drainage or aspiration of the abscess can result in treatment failure regardless of antibiotic choice, as warned by the American College of Clinical Pharmacology 1, 2

Antibiotic Therapy for Breast Abscess

Antibiotic Selection

• The Infectious Diseases Society of America recommends Dicloxacillin (500 mg QID) or cephalexin (500 mg QID) for methicillin-susceptible S. aureus (MSSA) infections, providing coverage against MSSA 7
• Amoxicillin-clavulanate (875/125 mg BID) provides broader coverage and is particularly useful for non-lactational abscesses that may have mixed flora, as suggested by the Clinical Infectious Diseases guideline 7